DK0952772T3 - Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration - Google Patents

Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration

Info

Publication number
DK0952772T3
DK0952772T3 DK96932991T DK96932991T DK0952772T3 DK 0952772 T3 DK0952772 T3 DK 0952772T3 DK 96932991 T DK96932991 T DK 96932991T DK 96932991 T DK96932991 T DK 96932991T DK 0952772 T3 DK0952772 T3 DK 0952772T3
Authority
DK
Denmark
Prior art keywords
methods
mononuclear phagocytes
mammal
axonal regeneration
nervous system
Prior art date
Application number
DK96932991T
Other languages
English (en)
Inventor
Michal Eisenbach-Schwartz
Orly Spiegler
David L Hirschberg
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0952772T3 publication Critical patent/DK0952772T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
DK96932991T 1995-09-15 1996-09-12 Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration DK0952772T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52884595A 1995-09-15 1995-09-15
US08/695,351 US5800812A (en) 1995-09-15 1996-08-09 Methods of use of mononuclear phagocytes to promote axonal regeneration
PCT/US1996/014578 WO1997009885A1 (en) 1995-09-15 1996-09-12 Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration

Publications (1)

Publication Number Publication Date
DK0952772T3 true DK0952772T3 (da) 2005-07-18

Family

ID=27062850

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96932991T DK0952772T3 (da) 1995-09-15 1996-09-12 Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration

Country Status (13)

Country Link
US (2) US5800812A (da)
EP (1) EP0952772B1 (da)
JP (1) JP4100707B2 (da)
AT (1) ATE290789T1 (da)
AU (1) AU714205B2 (da)
CA (1) CA2232262A1 (da)
DE (1) DE69634499T2 (da)
DK (1) DK0952772T3 (da)
ES (1) ES2241002T3 (da)
IL (1) IL123642A (da)
NZ (1) NZ319365A (da)
PT (1) PT952772E (da)
WO (1) WO1997009885A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
EP0996456A4 (en) * 1997-08-04 2003-07-09 Univ California PROCESS FOR TREATING NEUROLOGICAL DEFICITS
US7795202B2 (en) * 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
US20010007657A1 (en) * 1997-08-04 2001-07-12 Reid James Steven Compositions and methods for manipulating glial progenitor cells and treating neurological deficits
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
SE9802264D0 (sv) 1998-06-25 1998-06-25 Neuronova Ab A method of isolating cells
US6541247B1 (en) 1998-06-25 2003-04-01 Neuronova Ab Method of isolating ependymal neural stem cells
IL125983A0 (en) * 1998-08-30 1999-04-11 Yeda Res & Dev Pharmaceutical composition comprising factor xiiia
DE60220894T2 (de) * 2001-03-12 2008-02-28 Institute Of Gene And Brain Science Verwendung von interleukin-12 zur behandlung von nervenschäden
US8377692B2 (en) * 2001-11-21 2013-02-19 Yeda Research And Development Co., Ltd. Process for the manufacturing of human mononuclear phagocytic leukocytes
WO2003105750A2 (en) * 2002-06-14 2003-12-24 Yeda Research And Development Co. Ltd Antigen-presenting cells for neuroprotection and nerve regeneration
US20090010873A1 (en) * 2004-11-29 2009-01-08 Yeda Research And Development Co. Ltd. Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis
CN107595889A (zh) * 2008-09-12 2018-01-19 克里奥普拉斯低温生物有限公司 缺血性组织的细胞疗法
DK2790712T3 (da) 2011-12-14 2016-12-19 Yeda Res & Dev Human monocyt-subpopulation til behandling af skade på centralnervesystemet
US10188679B2 (en) 2013-05-22 2019-01-29 Yeda Research And Development Co. Ltd Human monocyte sub-population for treatment of eye diseases and disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157024A (en) * 1977-10-16 1992-10-20 Strategic Medical Research Corporation Method of enhancing the activity of phagocytes including macrophages, modulating the cellular or humoral immune response, and reducing the adverse effects of stress in warm blooded animals
IL71440A0 (en) * 1984-04-04 1984-07-31 Univ Ramot Composition for nerve regeneration
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
IL97365A0 (en) * 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
IL91459A0 (en) * 1989-08-28 1990-04-29 Yeda Res & Dev Oligodendrocyte inhibitory factor

Also Published As

Publication number Publication date
NZ319365A (en) 1999-08-30
JP4100707B2 (ja) 2008-06-11
EP0952772A4 (en) 2002-01-02
CA2232262A1 (en) 1997-03-20
DE69634499D1 (de) 2005-04-21
US5800812A (en) 1998-09-01
ATE290789T1 (de) 2005-04-15
US6117424A (en) 2000-09-12
AU714205B2 (en) 1999-12-23
AU7157296A (en) 1997-04-01
WO1997009885A1 (en) 1997-03-20
IL123642A0 (en) 1998-10-30
PT952772E (pt) 2005-07-29
DE69634499T2 (de) 2006-01-05
EP0952772B1 (en) 2005-03-16
IL123642A (en) 2005-08-31
ES2241002T3 (es) 2005-10-16
JPH11513370A (ja) 1999-11-16
EP0952772A1 (en) 1999-11-03

Similar Documents

Publication Publication Date Title
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
AR003989A1 (es) Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica.
ATE397457T1 (de) Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
DE69922933D1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
ATE310077T1 (de) Erzeugung von hämatopoietischen zellen aus multipotenten neuronalen stammzellen
DK1028737T3 (da) Humane mesenchymale stamceller fra perifert blod
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
Plaut et al. Increase in histamine receptors on thymus-derived effector lymphocytes during the primary immune response to alloantigens
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
DE69635924D1 (de) Isolierung und züchtung von schwannzellen
IL157841A0 (en) Activation of natural killer cells by adenosine a3 receptor agonists
BR0010702A (pt) Novas quinonas como terapias de doenças
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
ATE514771T1 (de) Haartransplantation
DK0850298T3 (da) Nervetransplantation under anvendelse af pluripotente neuroepitelceller
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
BR9612821A (pt) Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
BR0305018A (pt) Células dendrìticas tolerogênicas e usos terapêuticos para as mesmas
TR199801659T2 (xx) Yeni triazolopurinler, haz�rlama y�ntemi, ila� olarak kullan�m�.
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
NO20010488L (no) FremgangsmÕte ved ex vivo behandling av allogene og xenogene T-celler med gp39-antagonister
Mielcarek et al. Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model